Meeting
2013 ASCO Annual Meeting
Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts.
Authors
Henry Li
Crown Bioscience, Santa Clara, CA
Henry Li , Dawei Chen , Sheng Guo , Jie Cai , Yiyou Chen , Jean-Pierre Wery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3544)
DOI
10.1200/jco.2013.31.15_suppl.3544
Abstract #
3544
Poster Bd #
2B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.
First Author: Eiji Shinozaki
Poster
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
First Author: LI Liu
Poster
2021 ASCO Annual Meeting
Genomic profiling of KRAS wide-type pancreatic ductal adenocarcinomas identifies targetable genetic alterations.
First Author: Deng Wei
Poster
2020 Gastrointestinal Cancers Symposium
Molecular profiling of early-stage colorectal cancer (CRC) using targeted next generation sequencing (NGS) to predict signatures of recurrence.
First Author: Michael C. Burns